Diclofenac vs. Placebo in a Randomized Double Blind Controlled Trial in Post ERCP Pancreatitis
NCT ID: NCT01946984
Last Updated: 2013-09-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
182 participants
INTERVENTIONAL
2012-06-30
2013-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
2. Several studies showed that non-steroidal anti-inflammatory drugs (NSAIDs) can prevent the post ERCP pancreatitis, the investigators used diclofenac vs placebo.
3. The effect of diclofenac in prevention of that complication, was measured by the number of patients who developed pancreatitis, and compare it with the placebo.
4. The investigators collected 199 patients, 17 excluded, 182 completed the study, all of them underwent the intervention called "ERCP", and randomized to have either Diclofenac or Placebo before the procedure.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Between June 2012 and June 2013, 199 patients fulfilled the inclusion criteria, 182 of whom were included in the final analysis.
* Patients were excluded from study participation if they had a contraindication for diclofenac, including patients with recently diagnosed peptic ulcer disease, renal failure, those who developed acute pancreatitis during the two weeks before ERCP, those with a history of chronic pancreatitis, and those who did not agree to participate in the study.
* A placebo-controlled trial was conducted in 182 patients who underwent ERCP.
* Preoperative, the patients received 75 mg intramuscular(IM) diclofenac or IM normal saline as placebo. At the end of each procedure, the investigators recorded the details of the maneuvers performed, including:
1. the total time of the procedure,
2. the number of attempts at cannulation,
3. the number of pancreatic duct cannulation,
4. the final diagnosis by ERCP,
5. whether a sphincterotomy, a needle-knife papillotomy, or stent placement were performed.
* Serum amylase was determined 12 hours after ERCP.
* If the 12-hours serum amylase level was \> 3 times the upper normal limit and the patient exhibited pain or nausea and vomiting, then the patient had pancreatitis.
* Acute pancreatitis was defined as serum amylase \> 3 times the upper limit of normal and associated with epigastric pain, back pain, and epigastric tenderness.
* Statistical analysis:
1. Randomization was done by the GI nurse, concealed envelop
2. Data were summarized by descriptive statistics.
3. The Chi square was used to compare categorical patient data.
4. The Student's t test was used to compare continuous variables.
5. Two-tailed P \< 0.05 was considered to indicate significance.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Diclofenac,75 mg, 3 ml,
patients were given Diclofenac IM before ERCP.
ERCP
endoscopy, retrograde cholangio-pancreaticography.
Diclofenac hydroxyethylpyrrolidine
Normal Saline, 3ml, IM
patients were given normal saline 3 ml before ERCP
ERCP
endoscopy, retrograde cholangio-pancreaticography.
Normal Saline
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ERCP
endoscopy, retrograde cholangio-pancreaticography.
Diclofenac hydroxyethylpyrrolidine
Normal Saline
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
16 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Specialized Arab Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yasser Abu-Safieh
Associate Prof, MD, AGAF
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yasser Abu-Safieh, MD, AGAF
Role: PRINCIPAL_INVESTIGATOR
Specialized Arab Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
SAH hospital
Nablus, West Bank, Palestinian Territories
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Specialized Arab Hospital
Identifier Type: -
Identifier Source: org_study_id